Meet at DCAT Week 2026
Date: March 23-26, 2026
Location: Intercontinental Barclay | New York City
Address: 111 E 48th St, New York, NY 10017
Headquartered in Wilmington, Delaware, Noramco is a global supplier of active ingredients (APIs) including controlled substances to the pharmaceutical industry. Noramco’s APIs are used by many of the leading brand and generic pharma companies as well as small to mid- scale pharma companies. Noramco’s APIs are used in over 350 products and sold in over 30 counties. Noramco manufactures APIs that are used across a broad set of indications such as ADHD, pain management and abuse treatment and prevention. For more information, please visit www.noramco.com.
Headquartered in Athens, Georgia, Purisys is a leading supplier of API CDMO services and pharmaceutical reference standards. Its 17,000-square-foot manufacturing facility and innovation center is staffed by scientists, engineers, and other professionals who have decades of experience in complex high-barrier custom synthetic chemistry. Purisys’ CDMO services are designed to support the development of custom APIs for a wide range of clinical and niche commercial applications, including highly potent APIs and injectable-grade APIs. Purisys has specialized capabilities in controlled substance APIs, possessing 6 DEA registrations encompassing 48 drug codes. Purisys stocks a catalog of more than 250 commercial reference standards that support pharmaceutical drug product development and manufacturing. For more information, please visit www.purisys.com.
Halo Pharma is a rapidly growing contract development and manufacturing organization (CDMO) that provides scientific and development expertise as well as a wide spectrum of manufacturing services from its locations in Whippany, New Jersey, USA and Montreal, Quebec, Canada to its international client base. Halo offers fully integrated capabilities in a variety of dosage forms including tablets, capsules, powders, liquids, creams, sterile and non-sterile ointments and suppositories. The company is registered to work with any of these dosages in the CI-CV DEA designations. Halo Pharma’s capabilities in the areas of tech transfer, process and product development, production, scale-up/validation and analytical method development allow us to partner with clients from development through commercialization or at any point along the way. For more information please contact services@halopharma.com.